Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

This is a Phase I Clinical Study to Evaluate the Safety and Efficacy of CAR-T Infusion Preparation in the Treatment of CD19-positive Relapsed/Refractory Non-Hodgkin Lymphoma.

Next Previous
Trial Profile

This is a Phase I Clinical Study to Evaluate the Safety and Efficacy of CAR-T Infusion Preparation in the Treatment of CD19-positive Relapsed/Refractory Non-Hodgkin Lymphoma.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Puzolcabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Histiocytosis; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Chongqing Precision Biotech Co., Ltd

Most Recent Events

  • 12 Nov 2023 Planned End Date changed from 30 Sep 2024 to 30 Sep 2025.
  • 12 Nov 2023 Planned primary completion date changed from 30 Sep 2023 to 30 Sep 2024.
  • 22 Jun 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top